Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HitGen Enters Drug Discovery Collaboration with Scripps Research Institute

publication date: Apr 24, 2017
HitGen of Chengdu announced its fourth collaboration in three months: it will work with The Scripps Research Institute (TSRI) and its affiliate, the California Institute for Biomedical Research (Calibr), to discover and develop new small molecule drug candidates. Initially, the collaboration will target unmet needs in oncology, regenerative medicine and virology. Since February, HitGen has announced collaborations with Cancer Research UK, Merck/MSD and Pfizer. The technology behind HitGen's DNA encoded libraries was originally conceived at TSRI. More details...

Stock Symbols: (NYSE: MRK) (NYSE: PFE)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital